Innovations in AL Amyloidosis: What New Treatments and Research Mean for Patients
Join Dr. Rajshekhar Chakraborty, MD, as he shares the latest emerging clinical data and ongoing research in AL amyloidosis. This session will cover new therapies, evolving treatment strategies, and promising clinical trials, helping patients understand how advances in research may impact care and outcomes. Dr. Chakraborty will explain complex scientific information in clear, understandable terms and answer your questions during a live Q&A, empowering attendees with k
Type your questions in the chat and we will answer them!
Cindy introduces the agenda of the event and featured speaker Rajshekhar Chakraborty, MD
Dr. Chakraborty talks about treatments and research for amyloidosis patients
Cynthia Cahoon, RN
Cynthia is a newborn ICU nurse by trade that has spent the last six years in the medical device industry educating nurses and doctors about devices that are new to their facility. In her spare time she enjoys hiking, traveling the world with her family, and creating Halloween animatronics for her annual front yard display. She has a passion for life-long learning and enjoys sharing what she learns with the people around her.
Dr. Rajshekhar Chakraborty
Rajshekhar Chakraborty, MD is an assistant professor of medicine at Columbia University Irving Medical Center in the division of hematology/oncology. After receiving his medical degree from University of Delhi, India, he completed his residency in internal medicine at Icahn School of Medicine at Mount Sinai-Queens Hospital Center. Subsequently, he spent three years as a clinical researcher in plasma cell disorders at the Mayo Clinic, Rochester, followed by fellowship in hematology/oncology at the Cleveland Clinic. Dr. Chakraborty cares primarily for patients with plasma cells disorders, including multiple myeloma, amyloidosis, MGUS, POEMS syndrome, and Waldenstrom's macroglobulinemia. His research interests include clinical trials and outcomes research in plasma cell disorders.